The neomycin present in Idroneomicil is an antibiotic with a wide spectrum of action that includes gram + and gram – bacteria, it does not cause resistance in bacteria, it is active in the presence of pus and it is not irritating to mucous membranes and it is also extremely stable.
Hydrocortisone acetate eliminates the inflammatory reaction of the connective tissue, exerting an inhibitory action on fibroblasts and fibrocytes, mastocells and plasma cells and on reticulum endothelial cells in general, on the basal endothelium, collagen and reticular fibers. Hydrocortisone acetate is therefore very useful for eliminating the inflammatory reaction of the connective tissue in cases where there is an exaggerated mesenchymal involvement.
Naphthyl-methyl-imidazoline nitrate, a highly active vasoconstrictor, contributes to reducing, with its marked and prolonged therapeutic action, the inflammatory phenomena that initially manifest themselves through hyperemia.
Idroneomicil is indicated in infectious and inflammatory conditions of the ears, eyes and nose; as well as in sinusitis.
Eyes: Inflammatory eye conditions with associated bacterial infection or at risk of developing it, such as bacterial conjunctivitis, allergic conjunctivitis. Adding imidazoline to this combination decreases conjunctival hyperemia caused by vasodilation.
Ears: Idroneomicil is indicated in the treatment of acute otitis caused by germs sensitive to neomycin.
Nose: Allergic rhinitis, nasal congestion.
No significant interaction with another drug is known. Despite this, it should be noted that if systemic absorption of imidazoline occurs, its pressor effect may be potentiated with the concomitant use of tricyclic antidepressants. Systemic absorption of neomycin can inhibit the gastrointestinal absorption of penicillin, vitamin B12, methotrexate, and digoxin and may increase the effects of anti-coumarin drugs. Furthermore, hydrocortisone can decrease the action of oral hypoglycemic drugs.
In the oculistic field, prolonged use can give rise to hypersensitization phenomena; therefore, it is advisable to carry out frequent eye tone checks. The uninterrupted application for more than a month is not advisable.
When Idroneomicil is administered it should not be applied at the same time to the eyes, nose and ears to avoid possible contamination.
Each ml contains:
Neomycin sulfate 5 mg
Hydrocortisone acetate 10 mg
Naphthyl-methyl-imidazoline nitrate 1 mg
C.S. Isotonic Aqueous Suspension
Topical: eyes, ears and nose.
Eyes: Apply one or two drops of Idroneomicil to the bottom of the conjunctival sac of the affected eye, every 4 to 6 hours, according to the intensity of the condition to be treated. In complicated or severe cases it is recommended to start with applications every hour and then space the applications as the inflammation decreases.
Ears: Instill 3 drops into the ear canal of the affected ear, 3 times a day for 7 days.
Nose: Apply a dropper to both nostrils every 4 hours.
Maintenance dose: 2 or 3 applications per day.
Box containing dropper bottle with 5ml of suspension.
Store at a temperature not higher than 30 °C.